Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.59 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.59 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.59 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.59 |
| ▸ | PI4KA | P42356 | 1/20 | 0.59 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.59 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.59 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.55 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.55 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.49 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.49 |
| ▸ | FDPS | P14324 | 1/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
| ▸ | INPPL1 | O15357 | 4/20 | 0.45 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.44 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.44 |
| ▸ | BTK | Q06187 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21044243 | 0.83 | PRMT5 (0.49) | PIK3CDPIP5K1CPIK3CAPIK3CBPI4KA | |
| SCHEMBL12896100 | 0.83 | GABRA1 (0.54) | PIK3CDPIP5K1CPIK3CAPIK3CBPI4KA | |
| SCHEMBL21044298 | 0.81 | MKNK1 (0.64) | CYP11B1CYP11B2PRMT5WDR77MAP4K4 | |
| SCHEMBL21044053 | 0.80 | CYP11B1 (0.66) | PIK3CDPIP5K1CPIK3CAPIK3CBPI4KA | |
| SCHEMBL25099193 | 0.78 | RXRA (0.67) | PIK3CDPIP5K1CPIK3CAPIK3CBPI4KA | |
| SCHEMBL3940185 | 0.78 | PIK3CD (0.46) | PIK3CDPIP5K1CPIK3CAPIK3CBPI4KA | |
| Hydrochloric Acid SCHEMBL17673239 | 0.77 | PIK3CD (0.44) | PIK3CDPIP5K1CPIK3CAPIK3CBPI4KA | |
| SCHEMBL21044099 | 0.77 | CYP11B1 (0.60) | PIK3CGCYP11B1CYP11B2PRMT5WDR77 | |
| SCHEMBL25099190 | 0.76 | MKNK1 (0.55) | PIK3CDPIP5K1CPIK3CAPIK3CBPI4KA | |
| SCHEMBL11154615 | 0.75 | CYP3A4 (0.58) | CYP11B1CYP11B2MAP4K4MKNK1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3717459-B1 | COMPOUNDS | STEP PHARMA S A S (FR) | 2026-01-21 | — | — | EP | disclosed |
| EP-3768674-B1 | AMINOPYRIMIDINE DERIVATIVES AS CTPS1 INHIBITORS | STEP PHARMA S A S (FR) | 2024-01-03 | — | — | EP | disclosed |
| US-20230192673-A1 | Compounds | STEP PHARMA S.A.S. (FR) | 2023-06-22 | — | — | US | disclosed |
| US-20230192673-A1 | Compounds | STEP PHARMA S.A.S. (FR) | 2023-06-22 | — | — | US | disclosed |
| US-11655246-B2 | Aminothiazole compounds as inhibitors of CTPS1 | STEP PHARMA S.A.S. (FR) | 2023-05-23 | — | — | US | disclosed |
| US-11655246-B2 | Aminothiazole compounds as inhibitors of CTPS1 | STEP PHARMA S.A.S. (FR) | 2023-05-23 | — | — | US | disclosed |
| US-20210024507-A1 | Compounds | STEP PHARMA S A S (FR) | 2021-01-28 | — | — | US | disclosed |
| US-20210002269-A1 | COMPOUNDS | STEP PHARMA S.A.S. (FR) | 2021-01-07 | — | — | US | disclosed |
| WO-2019179652-A1 | AMINOPYRIMIDINE DERIVATIVES AS CTPS1 INHIBITORS | STEP PHARMA S.A.S. (FR) | 2019-09-26 | — | — | WO | disclosed |
| EP-3543232-A1 | AMINOPYRIMIDINE DERIVATIVES AS CTPS1 INHIBITORS | Step Pharma S.A.S. (FR) | 2019-09-25 | — | — | EP | disclosed |
| EP-3543232-A1 | AMINOPYRIMIDINE DERIVATIVES AS CTPS1 INHIBITORS | Step Pharma S.A.S. (FR) | 2019-09-25 | — | — | EP | disclosed |
| EP-3492454-A1 | COMPOUNDS | Step Pharma S.A.S. (FR) | 2019-06-05 | — | — | EP | disclosed |
| EP-3492454-A1 | COMPOUNDS | Step Pharma S.A.S. (FR) | 2019-06-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11655246-B2 | Aminothiazole compounds as inhibitors of CTPS1 | CTPS1, CTPS2, TBXAS1 | PIK3CD 2075/4885PIP5K1C 1422/4885PIK3CA 2545/4885 |
| US-20210024507-A1 | Compounds | CYP1A1, UGT1A1, CYP1A2 | PIK3CD 4015/4885PIP5K1C 3840/4885PIK3CA 2975/4885 |
| US-20230192673-A1 | Compounds | CYP1A1, UGT1A1, CYP1A2 | PIK3CD 4015/4885PIP5K1C 3840/4885PIK3CA 2975/4885 |
| US-20210002269-A1 | COMPOUNDS | UGT1A1, CYP1A1, CYP19A1 | PIK3CD 3859/4885PIP5K1C 3546/4885PIK3CA 2785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.